Long-term effects of lamivudine treatment in Japanese chronic hepatitis B patients

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 24

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

365

HTML

3823

Figures (1-2)

243

Tables (1-3)

255

Sum=4686

Jun 28, 2011 (publication date) through Feb 6, 2025

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Article

World J Gastroenterol. Jun 28, 2011; 17(24): 2945-2952
Published online Jun 28, 2011. doi: 10.3748/wjg.v17.i24.2945

Table 2 Comparison of the emergence of YMDD mutants during treatment by hepatitis B e antigen status of patients, median (range)

Characteristics	HBeAg negative (n = 36)	HBeAg positive (n = 25)	P-value
No. of men (%)	28 (78)	17 (68)	NS
Age (yr)	50 (29-69)	50 (28-60)	NS
HBV DNA level (log copies/mL)	5.8 (2.7-7.6)	7.6 (4.1-8.7)	< 0.0001
Patients with YMDD mutants (%)	33 (92)	23 (92)	NS
Virological breakthrough (%)	12 (33)	14 (56)	NS
Patients with flare-ups of hepatitis (%)	9 (25)	11 (44)	NS

HBeAg: Hepatitis B e antigen; HBV: Hepatitis B virus; NS: Not significant.

Citation: Murata M, Furusyo N, Unno M, Ogawa E, Toyoda K, Taniai H, Ohnishi H, Hayashi J. Long-term effects of lamivudine treatment in Japanese chronic hepatitis B patients. World J Gastroenterol 2011; 17(24): 2945-2952
URL: https://www.wjgnet.com/1007-9327/full/v17/i24/2945.htm
DOI: https://dx.doi.org/10.3748/wjg.v17.i24.2945